Stromal vascular fraction (SVF) plays a significant role in regenerative medicine and in the treatment of various disorders. Numerous pre-clinical and clinical investigations have been conducted to establish the potential role of stromal vascular fraction for the treatment of osteoarthritis, cartilage regeneration, rheumatoid arthritis, and several soft tissue diseases. Stromal vascular fraction is a promising tool in orthopaedics, owing to the anti-inflammatory, immune-modulation, and homeostatic properties of SVF, which is anticipated to offer growth opportunities for the stromal vascular fraction market. Besides, regenerative ability is derived from soluble factors that have multipotent differentiating capabilities, along with heterogeneous cell population containing pericytes, endothelial cells, leukocytes mesenchymal stem cells, and red blood cells. Also, SVF injections are a promising, insignificantly intrusive, non-surgical alternative in the field of orthopedics for the treatment of musculoskeletal disorders.
Increasing Clinical Trials for Efficient SVF-derived Cell Therapies
SVF therapies have huge potential in regenerative medicine, and a significant number of clinical trials are being conducted across the globe to evaluate the significance of SVF isolation and processing techniques for different indications. These clinical trials use proprietary SVF isolation, aspiration, and transfer devices, thus, significantly boosting the growth of the stromal vascular fraction market. Most of these trials are being conducted in the matured market of the U.S. For instance, in 2019, Healeon Medical Inc. evaluated Centricyte 1000, a closed system digestion of stromal vascular fraction, for use in frailty and aging processes to improve quality of life and functional health. Orthopedic and neurological applications are found to be most attractive in the field of stromal vascular fraction or adipose-derived stem cell therapy.
Increasing Demand for Non-enzymatic Isolation of Stromal Vascular Fraction to Benefit Market
Non-enzymatic isolation methods utilize physical forces to separate cells from adipose matrix. Mechanical segregation strategies are alternatives to circumvent safety issues posed by enzymatic protocols. Non-enzymatic protocols have been endeavored comprising of precisely separating SVF using different devices or an automated closed system, resulting in ready-to-use SVF. To overcome concerns such as high cost, long protocol duration, and regulatory scrutiny, the adoption of non-enzymatic alternatives is increasing for improved volume retention of fat grafts. In addition, simplification of the technique with improved standardization along with reducing operator-dependent variations makes the non-enzymatic isolation technique more approachable in a clinical practice, and significantly aids the growth of the stromal vascular fraction market.
North America to Dominate Stromal Vascular Fraction Market
North America holds a noteworthy share in the stromal vascular fraction market, with 37% of total revenue, and is expected to exhibit a CAGR of around 4% during the forecast period. Growing incidence of skeletal muscular disorders such as osteoarthritis, increasing awareness about stem cell therapy, increasing volume of cosmetic surgeries, and rising demand among clinicians are factors expected to contribute to the dominance of North America in the global stromal vascular fraction market. Owing to increase in research & development activities in the development of innovative technologies and increasing preference for SVF as an alternative option for better clinical solutions have represented a continuous rise in the demand for advanced technologies, and expansion of private hospitals in rural areas are boosting the demand for stromal vascular fraction in Asia Pacific, which represents the second-most attractive market; it is expected to grow at a CAGR of 4.5% over the forecast period. Europe is projected to be the third-most lucrative region in the global stromal vascular fraction market, and is expected to exhibit a CAGR of 3.5% during the forecast period.
Competitive Landscape of Stromal Vascular Fraction Market
The market is characterized as a fragmented space, with a few key players operating across the globe, such as Cytori Therapeutics Inc., Cellular Biomedicine Group, and others. Investment in R&D to launch new product lines is a key strategy being adopted by manufacturers in the stromal vascular fraction market. LipoCell from Tissyou, is a promising class IIa medical device that exploits an innovative technology to allow harvesting, which is effective in optimizing fat tissue recuperation for subsequent autologous infusion.
Technological innovations for new product launches and rising demand for SVF in regeneration medication are responsible for the growth of the stromal vascular fraction market at an impressive rate, with North America and Europe holding substantial share of the global stromal vascular fraction market. Solid monetary position and new collaboration for the effective management of intravenous infusion are expected to drive the growth of the stromal vascular fraction market over the coming years.
Stromal Vascular Fraction Market: Scope of the Report
Persistence Market Research (PMR) recently published a market study on the global stromal vascular fraction market. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities restraints, and detailed information about the stromal vascular fraction market structure. The market study presents exclusive information about how the stromal vascular fraction market will grow during the forecast period (2019-2029).
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compound annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes definition, drivers and opportunity analysis by region, which helps in deep understanding of the market segment with details about researchers, suppliers, manufactures, and distributors. This information can help readers understand the quantitative growth prospects of the stromal vascular fraction market for the forecast period.
The study is relevant for manufacturers, physicians, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Business researcher, shareholders, industry experts can leverage the information and data presented in PMR’s study.
The study also includes statistics as well as facts related to macroeconomics factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the stromal vascular fraction market. Furthermore, small businesses and new entrants in the stromal vascular fraction market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.
Key Segments of Stromal Vascular Fraction Market
PMR’s study on the stromal vascular fraction market offers information divided into four important segments - product, application, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Questions Answered in PMR’s Stromal Vascular Fraction Market Report
Stromal Vascular Fraction Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the stromal vascular fraction market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analyst ensure accuracy and reliability of conclusions.
Secondary resources referred to analyst during the production of the stromal vascular fraction market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories, and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in SVF isolation devices, and makes PMR’s projection on the growth prospects of the stromal vascular fraction market more accurate and reliable.